Evoq Remedies has filed its financial results for the half-year and year with a qualified audit opinion, citing significant doubt about its ability to continue as a going concern.

Key concerns include unapproved related-party loans of 6.70 Cr, unconfirmed debtors (3.85 Cr) and supplier advances (12.51 Cr), and unpaid income tax (0.62 Cr) and TDS (0.39 Cr). Business operations are severely curtailed, and the company faces a SEBI investigation into financial integrity and preferential issue fund utilization.

Evoq Remedies reported a net loss of 0.25 Cr for the year.

Management, while believing assets are recoverable, is initiating corrective actions.